327 related articles for article (PubMed ID: 22076962)
1. Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin.
Twilla JD; Finch CK; Usery JB; Gelfand MS; Hudson JQ; Broyles JE
J Hosp Med; 2012 Mar; 7(3):243-8. PubMed ID: 22076962
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.
Chuang YC; Wang JT; Lin HY; Chang SC
BMC Infect Dis; 2014 Dec; 14():687. PubMed ID: 25495779
[TBL] [Abstract][Full Text] [Related]
3. Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus.
Patel K; Kabir R; Ahmad S; Allen SL
J Oncol Pharm Pract; 2016 Apr; 22(2):212-8. PubMed ID: 25326010
[TBL] [Abstract][Full Text] [Related]
4. Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan.
Chou CH; Lee NY; Lee HC; Chang CM; Lee CC; Ko WC
J Microbiol Immunol Infect; 2012 Jun; 45(3):221-7. PubMed ID: 22578639
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Usery JB; Vo NH; Finch CK; Cleveland KO; Gelfand MS; Self TH
Am J Med Sci; 2015 Jan; 349(1):36-41. PubMed ID: 25233042
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
Mave V; Garcia-Diaz J; Islam T; Hasbun R
J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin-resistant enterococcal bacteremia pharmacotherapy.
Patel R; Gallagher JC
Ann Pharmacother; 2015 Jan; 49(1):69-85. PubMed ID: 25352037
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
Scheetz MH; Qi C; Noskin GA; Warren JR; Postelnick MJ; Malczynski M; Huang J; Zembower TR
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):407-13. PubMed ID: 16930924
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
[TBL] [Abstract][Full Text] [Related]
10. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia.
Balli EP; Venetis CA; Miyakis S
Antimicrob Agents Chemother; 2014; 58(2):734-9. PubMed ID: 24247127
[TBL] [Abstract][Full Text] [Related]
12. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.
Britt NS; Potter EM; Patel N; Steed ME
Clin Infect Dis; 2015 Sep; 61(6):871-8. PubMed ID: 26063715
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin.
Rathe M; Kristensen L; Ellermann-Eriksen S; Thomsen MK; Schumacher H
APMIS; 2010 Jan; 118(1):66-73. PubMed ID: 20041873
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-effectiveness of alternative empiric antimicrobial treatment options for suspected enterococcal bacteremia.
McComb MN; Collins CD
Pharmacotherapy; 2014 Jun; 34(6):537-44. PubMed ID: 24390863
[TBL] [Abstract][Full Text] [Related]
17. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.
Crank CW; Scheetz MH; Brielmaier B; Rose WE; Patel GP; Ritchie DJ; Segreti J
Clin Ther; 2010 Sep; 32(10):1713-9. PubMed ID: 21194593
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
King EA; McCoy D; Desai S; Nyirenda T; Bicking K
J Antimicrob Chemother; 2011 Sep; 66(9):2112-8. PubMed ID: 21697178
[TBL] [Abstract][Full Text] [Related]
19. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
20. Optimizing therapy for vancomycin-resistant enterococcal bacteremia in children.
Tamma PD; Hsu AJ
Curr Opin Infect Dis; 2014 Dec; 27(6):517-27. PubMed ID: 25313503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
